Inhibikase Therapeutics, Inc. Common Stock (NASDAQ: IKT) last traded at $1.85, down 6.35% on the session. The quote above updates while this page is open; the figures below are drawn from Inhibikase Therapeutics, Inc. Common Stock’s own filings and are restated only when a new one is published.
Inhibikase Therapeutics, Inc. Common Stock trades on NASDAQ under the ticker IKT. Its market capitalisation is $257.44 million.
Valuation measures for Inhibikase Therapeutics, Inc. Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $257.44M |
|---|---|
| Enterprise value | $88.90M |
| Price / book | 1.68 |
| Beta | 1.40 |
Trailing-twelve-month figures tagged in Inhibikase Therapeutics, Inc. Common Stock's XBRL filings with the SEC.
| Net income (TTM) |
|---|
| -$60.64M |
| EPS (TTM) | -$0.440 |
|---|
| Return on equity | -39.55% |
|---|
| Cash | $178.80M |
|---|
Range and volume for IKT over the past 52 weeks.
| 52-week high | $2.61 |
|---|---|
| 52-week low | $1.33 |
| Volume | 741.2K |
| Average volume | 651.9K |
| Previous close | $1.97 |
Invest a chosen dollar amount in Inhibikase Therapeutics, Inc. Common Stock with fractional shares.
Start investingCreate an account
Investing involves risk, including possible loss of principal. Nothing here is investment advice or a recommendation to buy or sell IKT.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.